Radioimmunotherapy with alpha-particle emitting radionuclides.
An important consideration in the development of effective strategies for radioimmunotherapy is the nature of the radiation emitted by the radionuclide. Radionuclides decaying by the emission of alpha-particles offer the possibility of matching the cell specific reactivity of monoclonal antibodies with radiation with a range of only a few cell diameters. Furthermore, alpha-particles have important biological advantages compared with external beam radiation and beta-particles including a higher biological effectiveness, which is nearly independent of oxygen concentration, dose rate and cell cycle position. In this review, the clinical settings most likely to benefit from alpha-particle radioimmunotherapy will be discussed. The current status of preclinical and clinical research with antibodies labeled with 3 promising alpha-particle emitting radionuclides - (213)Bi, (225)Ac, and (211)At - also will be summarized.
Zalutsky
M R
MR
Department of Radiology, Duke University Medical Center, Durham, NC 27710, USA. zalut001@mc.duke.edu
Pozzi
O R
OR
D000186:Actinium / Q000627:therapeutic use*; D000512:Alpha Particles / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001246:Astatine / Q000627:therapeutic use*; D001729:Bismuth / Q000627:therapeutic use*; D006801:Humans; D007554:Isotopes / Q000627:therapeutic use; D009369:Neoplasms / Q000532:radiotherapy*; D010818:Practice Patterns, Physicians'; D016499:Radioimmunotherapy / Q000379:methods*; D011868:Radioisotopes / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D007554:Isotopes; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D000186:Actinium; D001729:Bismuth; D001246:Astatine